Abstract:Abstract Abstract 2862 Poster Board II-838 Multiple myeloma (MM) is an incurable hematologic tumor caused by malignant transformation of plasma cells. JAZ (just another zinc finger protein) was previously identified in our laboratory as a unique ZFP that preferentially binds to double-stranded (ds) RNA rather than dsDNA. The JAZ gene is localized to the human chromosome 5q35-ter, which is a specific chromosomal region at which deletions and translocations occur in different hematologic malignancies including multiple myeloma. The NCI Cancer Genome Anatomy Project data base search reveals that a validated SNP (single nucleotide polymorphism) exists for JAZ at an evolutionarily conserved, 3'-untranslated, regulatory region of JAZ mRNA. This specific SNP exists only in the bone marrow cancer but not in the normal tissue, suggesting a potential role for JAZ in hematologic malignancies. Importantly, we recently discovered JAZ as a novel direct, positive regulator of p53 transcriptional activity. The mechanism involves direct binding to p53's C-terminal (negative) regulatory domain to activate “latent” p53 in response to non-genotoxic stress signals. Moreover, we found that interleukin-3 growth factor withdrawal upregulates JAZ expression in factor-dependent hematopoietic cells in association with activation of the p53 tumor suppressor and induction of apoptotic cell death, indicating that the expression of JAZ is important in the stress response. Thus, to examine the role of JAZ expression in hematologic malignancies, we carried out an immunohistochemistry (IHC) study of JAZ expression in murine and human bone marrow cells and in normal and malignant hematologic tissues and cell lines. The affinity-purified rabbit polyclonal antibody JAZ111 was used and its specificity was verified by the peptide inhibition and also using a commercially available monoclonal antibody against JAZ. Results reveal that JAZ is differentially expressed in different types or stages of hematopoietic cells. For instance, morphologically, JAZ appears to be (relatively) abundantly expressed in plasma cells in normal bone marrow samples and such observation was verified by co-staining with a CD38 antibody. Interestingly, results of JAZ111 staining of an MM tissue microarray (24 cases/48 cores, 13 MM and 11 normal tissues) reveal that in ∼50 % of the MM samples the expression of JAZ is substantially down-regulated compared to the normal tissue controls. This supports the notion that JAZ may play a tumor suppressor role. However, there are exceptions that JAZ was found to be highly or over-expressed in some MM samples on the microarray and other regular individual sample slides, suggesting that JAZ may be latent or inactivated in these cases. Co-staining of the MM samples with a p53 antibody shows that expression of p53 is low, which agrees with the notion that p53 expressed in the MM samples is usually the wild type but in a latent state since the p53 gene has been reported to be rarely mutated and the p53 pathway remains intact in multiple myeloma. Thus, we hypothesize that activation or reactivation of JAZ in the MM cells which express abundant but latent JAZ may induce p53 activation to arrest or kill MM cells. We have explored JAZ as a potentially novel molecular target in multiple myeloma by identifying small molecules that bind and activate JAZ. Using a high-throughput, “molecular docking” strategy, we have screened approximately 240,000 small molecules for their ability to interact with JAZ. Based on the Lipinski Rules for Drug Likeness (molecular characteristics favorable for absorption and permeability), we identified ∼70 putative “drug-like” binding molecules with high scores and obtained ∼40 of them from the NCI Developmental Therapeutics Program. We performed the cell viability study, flow cytometry and Western blot analysis to test their effect on the MM cell lines. Results demonstrate that several of the “candidate” JAZ-targeting compounds can potently induce growth arrest and/or cell death in association with p53 activation. Therefore, while further in vitro and in vivo characterization remains to be carried out, the JAZ-“targeting” compounds point the way to develop a potentially novel therapeutic strategy targeting JAZ to treat multiple myeloma. Disclosures: No relevant conflicts of interest to declare.

IKZF1 Selectively Enhances Homologous Recombination Repair by Interacting with CtIP and USP7 in Multiple Myeloma

Macrophages Promote DNA Repair of Double Strand Break in Multiple Myeloma Cells by Non-Homologous End Joining(nhej), Nevertheless Sacrifice the Accuracy of NHEJ

Macrophages Promote Dna Repair Of Double Strand Break In Multiple Myeloma Cells By Non-Homologous End Joining(Nhej), Nevertheless Decrease Its Accuracy

Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader

Super Enhancer-Mediated Upregulation Ofhjurppromotes Growth and Survival of T(4;14)-Positive Multiple Myeloma

Pharmacological Inhibition of EZH2 Combined with DNA‑damaging Agents Interferes with the DNA Damage Response in MM Cells.

HMGB1 Knockdown Increases MM Cell Vulnerability by Regulating Autophagy and DNA Damage Repair

ZNF506-dependent positive feedback loop regulates H2AX signaling after DNA damage

Author Correction: the Bromodomain Containing Protein BRD-9 Orchestrates RAD51–RAD54 Complex Formation and Regulates Homologous Recombination-Mediated Repair

ZNF830 mediates cancer chemoresistance through promoting homologous-recombination repair.

Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy

Inhibition of Pim-2 Kinase by LT-171-861 Promotes DNA Damage and Exhibits Enhanced Lethal Effects with PARP Inhibitor in Multiple Myeloma.

ZNF655 involved in the progression of multiple myeloma via the activation of AKT

Abstract PO1-13-11: ZNF689 Promotes Homologous Recombination Via NBS1 Ubiquitination and Its Loss Confers Sensitivity to PARP Inhibition in Triple-Negative Breast Cancer

Deregulation of DNA Double-Strand Break Repair in Multiple Myeloma: Implications for Genome Stability

Epigenetic Identification, of Znf545 As A Functional Tumor Suppressor in Multiple Myeloma Via Activation of P53 Signaling Pathway

Expression Of Jaz In Multiple Myeloma And Its Potential Role As A Novel Molecular Target

CRIP1 INDUCES PIS RESISTANCE BY FORMING A COMPLEX WITH USP7 /PA200 AND ENHANCING PROTEASOME ACTIVITY AND AUTOPHAGY IN MULTIPLE MYELOMA

Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma

Non Homologous End Joining, A Marker of Genomic Instability is Elevated in Multiple Myeloma: A New Prognostic Factor

Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells.